52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience

This publication has 15 references indexed in Scilit:

• Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
  Journal of the European Academy of Dermatology and Venereology, 2022
• A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
  Dermatology and Therapy, 2022
• Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
  Clinical and Experimental Dermatology, 2021
• Successful management of treatment resistant nail psoriasis with tildrakizumab
  Australasian Journal of Dermatology, 2021
• Psoriasis
  The Lancet, 2021
• Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
  British Journal of Dermatology, 2021
• Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
  American Journal of Clinical Dermatology, 2020
• Definition of minimal disease activity in psoriasis
  Journal of the European Academy of Dermatology and Venereology, 2020
• Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
  British Journal of Dermatology, 2019
• A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
  Journal of Dermatological Treatment, 2018